浙江天册律师事务所 关于 浙江圣达生物药业股份有限公司 2025 年第二次临时股东大会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼邮编 310007 电话：0571 8790 111 传真：0571 8790 1500 https://www.tclawfirm.com/ 法律意见书 浙江天册律师事务所 关于浙江圣达生物药业股份有限公司 2025 年第二次临时股东大会的 法律意见书 编号：TCYJS2025H1218 号 一、本次股东大会召集、召开的程序 （一）经本所律师核查，公司本次股东大会由董事会提议并召集，召开本次股 东大会的通知已于 2025 年 7 月 8 日在指定媒体及上海证券交易所网站上公告。 （二）本次股东大会采取现场投票与网络投票相结合的方式。 法律意见书 根据本次股东大会的会议通知，本次股东大会现场会议召开的时间为 2025 年 7 月 23 日 13 点 30 分；召开地点为浙江省天台县福溪街道始丰东路 18 号，公司会 议室。经本所律师的审查，本次股东大会现场会议召开的实际时间、地点与本次股 东大会的会议通知中所告知的时间、地点一致。 致：浙江圣达生物药业股 ...

证券代码：603079 证券简称：圣达生物 公告编号：2025-039 浙江圣达生物药业股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 7 月 23 日 (二)股东大会召开的地点：浙江省天台县福溪街道始丰东路 18 号,公司会议室 1、 议案名称：《关于修改<公司章程>并办理工商变更登记的议案》 审议结果：通过 表决情况： | 股东类型 | 同意 | | 反对 | | 弃权 | | | --- | --- | --- | --- | --- | --- | --- | | | 票数 | 比例（%） | 票数 | 比例 | 票数 | 比例 | | | | | | （%） | | （%） | | A 股 | 92,128,565 | 99.9174 | 48,156 | 0.0522 | 28,000 | 0.0304 | (三)出席会议的普通股股东和恢复表决权的优先股股 ...

Core Points - The company, Zhejiang Shengda Biological Pharmaceutical Co., Ltd., is holding its second extraordinary general meeting of shareholders on July 23, 2025, to discuss important matters including amendments to the Articles of Association [1][2][4]. Meeting Details - The meeting will take place at the company's conference room located at 18 Shifeng East Road, Fuxi Street, Tiantai County, Zhejiang Province, starting at 13:30 [1]. - Shareholders can participate through both on-site attendance and online voting via the Shanghai Stock Exchange's voting system during specified time slots on the same day [2][4]. Agenda Items - The primary agenda item is to amend the Articles of Association and handle the necessary business registration changes [1][5]. - The company has completed the issuance of 17,840,666 shares, increasing the total number of shares from 171,188,958 to 189,029,624, which raises the registered capital from 171,188,958 RMB to 189,029,624 RMB [4][5]. Changes to Company Structure - The name of one of the company's founders, Zhejiang Hongbo Enterprise Management Co., Ltd., will be changed to Ningbo Xuande Investment Co., Ltd. [5]. - Specific clauses in the Articles of Association will be revised to reflect the changes in total shares and registered capital, while other contents will remain unchanged [5][6]. Legal and Procedural Aspects - The meeting will be conducted in accordance with the company's Articles of Association and relevant laws, ensuring the protection of shareholders' rights and orderly proceedings [2][4]. - A legal representative from Zhejiang Tiance Law Firm will be present to witness the meeting and provide a legal opinion [4].

证券代码：603079 浙江圣达生物药业股份有限公司 2025 年第二次临时股东大会会议材料 二〇二五年七月 浙江圣达生物药业股份有限公司 2025 年第二次临时股东大会会议材料 | 目录 | | --- | | 2025 | 年第二次临时股东大会会议议程 | | 1 | | --- | --- | --- | --- | | 2025 | 年第二次临时股东大会会议须知 | | 3 | | 议案一：关于修改《公司章程》并办理工商变更登记的议案 | | 5 | | 浙江圣达生物药业股份有限公司 2025 年第二次临时股东大会会议材料 浙江圣达生物药业股份有限公司 2025 年第二次临时股东大会会议议程 一、会议时间 现场会议：2025 年 7 月 23 日(星期三)下午 13:30 网络投票：2025 年 7 月 23 日(星期三)采用上海证券交易所网络 投票系统，通过交易系统投票平台的投票时间为股东大会召开当日的 交 易 时 间 段 ， 即 2025 年 7 月 23 日 9:15-9:25 ， 9:30-11:30 ， 13:00-15:00；通过互联网投票平台的投票时间为股东大会召开当日 的 9:15-1 ...

[Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) The company anticipates substantial growth in its 2025 semi-annual performance, with significant increases in both net profit and non-recurring net profit attributable to shareholders 2025 Semi-Annual Performance Forecast vs. Prior Period | Indicator | 2025 Semi-Annual Forecast | 2024 Semi-Annual (Prior Period) | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | RMB 35 million - RMB 45 million | RMB 16.4948 million | 112.19% - 172.81% | | **Net Profit Attributable to Shareholders After Non-Recurring Items** | RMB 32 million - RMB 42 million | RMB 5.1514 million | 521.19% - 715.31% | - This performance forecast applies to situations where profitability is achieved, and net profit increases by **over 50%** compared to the same period last year[3](index=3&type=chunk) - The performance forecast period is from January 1, 2025, to June 30, 2025[4](index=4&type=chunk) - The company explicitly states that this performance forecast data has not been audited by a certified public accountant[5](index=5&type=chunk) [Prior Period Performance Overview](index=2&type=section&id=II.%20Prior%20Period%20Performance%20Overview) Key financial data for the first half of 2024 is provided as a benchmark, including net profit and non-recurring net profit attributable to the parent company 2024 Semi-Annual Key Financial Data | Indicator | 2024 Semi-Annual Data | | :--- | :--- | | **Total Profit** | RMB 24.1930 million | | **Net Profit Attributable to Shareholders** | RMB 16.4948 million | | **Net Profit Attributable to Shareholders After Non-Recurring Items** | RMB 5.1514 million | | **Earnings Per Share** | RMB 0.1/share | [Main Reasons for Performance Pre-Increase](index=2&type=section&id=III.%20Main%20Reasons%20for%20Current%20Period%20Performance%20Pre-Increase) Performance growth is primarily driven by optimized internal management, enhanced operational efficiency, and successful market expansion strategies - Internal Management Improvement: Continuous advancement of refined management and technological upgrades has enhanced operational efficiency and optimized costs[7](index=7&type=chunk) - Successful Market Strategy: Deepening differentiated competitive strategies and increasing market expansion efforts for bio-preservatives and functional ingredients have driven growth in this business segment[7](index=7&type=chunk) [Risk Warning and Other Disclosures](index=2&type=section&id=IV.%20Risk%20Warning) The company confirms no significant uncertainties affecting the forecast, reminding investors that preliminary data is subject to the final audited semi-annual report - The company confirms there are no other uncertain factors that could significantly impact the content of this performance forecast[8](index=8&type=chunk) - The company reminds investors that the forecast data is a preliminary calculation by the finance department and has not been audited; the final accurate data will be based on the company's officially disclosed 2025 semi-annual report, and investment risks should be noted[9](index=9&type=chunk)

Group 1: Annual Reports and Dividends - Gujinggong Liquor (000596) reported 2024 revenue of 23.578 billion yuan, up 16.41%, and net profit of 5.517 billion yuan, up 20.22%. The company plans to distribute a cash dividend of 50 yuan per 10 shares, totaling 2.643 billion yuan [2] - Luzhou Laojiao (000568) reported 2024 revenue of 31.196 billion yuan, up 3.19%, and net profit of 13.473 billion yuan, up 1.71%. The company plans to distribute a cash dividend of 45.92 yuan per 10 shares, totaling 6.759 billion yuan [2] - Gree Electric (000651) reported 2024 revenue of 189.164 billion yuan, down 7.26%, and net profit of 32.185 billion yuan, up 10.91%. The company plans to distribute a cash dividend of 20 yuan per 10 shares, totaling 11.17 billion yuan [3] Group 2: Q1 2025 Performance - Gujinggong Liquor reported Q1 2025 revenue of 9.146 billion yuan, up 10.38%, and net profit of 2.330 billion yuan, up 12.78% [2] - Gree Electric reported Q1 2025 revenue of 41.507 billion yuan, up 14.14%, and net profit of 5.904 billion yuan, up 26.29% [3] - National City Mining (000688) reported Q1 2025 revenue of 0.053 billion yuan, up 77.25%, and net profit of 0.0612 billion yuan, up 18279.65% [4] - Taiyuan Iron & Steel (000825) reported Q1 2025 revenue of 23.31 billion yuan, down 4.71%, and net profit of 0.0188 billion yuan, up 5506.92% [4] - Shenfang A (000029) reported Q1 2025 revenue of 0.033 billion yuan, up 457.38%, and net profit of 0.0724 billion yuan, up 3718.51% [4] - Qingda Environmental Protection (688501) reported Q1 2025 revenue of 0.0619 billion yuan, up 317.43%, and net profit of 0.0687 billion yuan, up 990.26% [4] - Tianbao Infrastructure (000965) reported Q1 2025 revenue of 0.0169 billion yuan, down 34.62%, and net profit of 0.01 billion yuan, up 737.29% [4] - Taihe Intelligent (603656) reported Q1 2025 revenue of 0.0105 billion yuan, up 10.19%, and net profit of 0.0002097 billion yuan, up 716.41% [5] - Meg Intelligent (002881) reported Q1 2025 revenue of 0.0997 billion yuan, up 73.57%, and net profit of 0.0463 billion yuan, up 616.02% [5] - Shengda Biological (603079) reported Q1 2025 revenue of 0.0203 billion yuan, up 9.95%, and net profit of 0.0217 billion yuan, up 469.35% [5] - Jincai Interconnection (002530) reported Q1 2025 revenue of 0.0206 billion yuan, down 33%, and net profit of 0.001364 billion yuan, up 466.95% [5] - XinSai Co. (600540) reported Q1 2025 revenue of 1.215 billion yuan, up 312.03%, and net profit of 0.01819 billion yuan, up 315.74% [6]

Core Viewpoint - The company has announced the use of idle raised funds for cash management, specifically investing in structured deposits with a total amount of 80 million RMB, aiming to enhance the efficiency of fund utilization and increase returns for the company and its shareholders [1][2][8]. Summary by Relevant Sections Investment Overview - The purpose of the investment is to improve the efficiency of raised funds and ensure that the investment does not affect the construction and use of the raised funds, while also increasing returns for the company and shareholders [2][9]. - The total amount for cash management is set at 80 million RMB, with a maximum limit of 230 million RMB for temporary idle funds [1][2]. - The funds are sourced from a specific stock issuance approved by the China Securities Regulatory Commission, raising a total of 267.61 million RMB, with a net amount of 261.42 million RMB after deducting issuance costs [2][3]. Investment Details - The investment will be made in structured deposits from China Construction Bank, with a principal amount of 40 million RMB and a term of 32 days, expected to yield a floating return [5][8]. - The expected annualized return ranges from 0.65% to 2.4%, depending on market conditions [5][7]. Approval and Compliance - The investment plan was approved during the 18th meeting of the fourth board of directors and the 16th meeting of the supervisory board on July 7, 2025, and does not require further shareholder approval [1][8][10]. - The company will manage the cash management products in compliance with relevant regulations and ensure that the funds are returned to the special account for raised funds upon maturity [8][10]. Impact on Operations - The use of idle funds for cash management is not expected to affect the company's daily operations or the normal progress of investment projects, and it aims to enhance the returns on cash assets [9][10]. - The company will adhere to the "New Financial Instruments Standards" in handling the cash management products, which may impact various financial statement items [9][10]. Monitoring and Risk Management - The company will maintain close contact with financial institutions to monitor the operation of cash management funds and strengthen risk control [10]. - The supervisory board and the sponsor institution have confirmed that the decision-making and approval processes are legal and compliant, ensuring no harm to the interests of the company and its shareholders [10][11].

证券代码：603079 证券简称：圣达生物 公告编号：2025-037 浙江圣达生物药业股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资种类：中国建设银行浙江分行单位人民币定制型结构性存款 投资额度：8,000.00万元 已履行的审议程序：浙江圣达生物药业股份有限公司（以下简称"公 司"）于2025年7月7日召开第四届董事会第十八次会议和第四届监事会第十六次 会议，审议通过了《关于使用闲置募集资金进行现金管理的议案》，同意公司及 子公司使用额度不超过人民币23,000.00万元的暂时闲置募集资金进行现金管理， 用于购买安全性高、流动性好、有保本约定、产品期限不超过12个月的银行等金 融机构现金管理产品（包括但不限于结构性存款、大额存单等）。在上述期限及 额度内，资金可滚动使用，并授权公司董事长最终审定并签署相关实施协议或者 合同等文件。保荐机构对此出具了明确的核查意见。 特别风险提示：尽管公司使用闲置募集资金进行现金管理购买的产品属于 低风险投资品种 ...

Core Points - Zhejiang Shengda Bio-Pharm Co., Ltd. is established as a joint-stock company in accordance with the Company Law and other relevant regulations [2][4] - The company was approved by the China Securities Regulatory Commission to issue 20 million shares of common stock to the public and was listed on the Shanghai Stock Exchange on August 23, 2017 [2][4] - The registered capital of the company is RMB 189,029,624 [3][4] - The company's business scope includes drug production, feed additives production, food additives production, and hazardous chemicals production, among others [4][5] Company Structure - The company is structured as a permanent joint-stock company with all assets divided into equal shares, and shareholders are liable for the company's debts only to the extent of their subscribed shares [3][4] - The company has established a party organization in accordance with the regulations of the Communist Party of China, which plays a political core role within the company [2][3] Share Issuance and Management - The shares of the company are issued in the form of stocks, with each share having a par value of RMB 1 [5][6] - The total number of shares issued by the company is 189,029,624, all of which are common shares [6][7] - The company cannot provide any financial assistance to individuals or entities purchasing its shares [6][7] Shareholder Rights and Responsibilities - Shareholders have the right to receive dividends and participate in shareholder meetings, as well as the obligation to comply with laws and regulations [12][13] - The company must maintain a shareholder register based on the records provided by the securities registration agency [12][13] Shareholder Meetings - The company holds annual and temporary shareholder meetings, with the annual meeting required to be held within six months after the end of the previous fiscal year [43][44] - Shareholder meetings must be conducted in accordance with legal and regulatory requirements, and the company must provide legal opinions on the meeting's compliance [46][47] Voting and Resolutions - Resolutions at shareholder meetings can be classified as ordinary or special, with ordinary resolutions requiring a simple majority and special resolutions requiring a two-thirds majority [76][77] - The company must ensure that voting rights are exercised fairly, and any related party transactions must be disclosed and voted on without the participation of related shareholders [80][81]

Meeting Overview - The fourth supervisory board meeting of Zhejiang Sandar Biopharmaceutical Co., Ltd. was held on July 7, 2025, with all three supervisors present, confirming the legality and validity of the meeting procedures [1][2]. Resolutions Passed - The supervisory board approved the proposal to use raised funds to replace pre-invested project funds and paid issuance expenses, with a unanimous vote of 3 in favor [1][2]. - The board also approved the proposal to provide loans from raised funds to the controlling subsidiary for project implementation, again with a unanimous vote of 3 in favor [2]. - A resolution was passed to manage idle raised funds for cash management purposes, receiving unanimous approval [2]. - The board approved the use of idle self-owned funds for cash management, also with unanimous support [2][3].